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Abstract
Background: Growing evidence suggests that hepatitis C virus (HCV) contributes to hepatocellular carcinoma (HCC)
by directly modulating oncogenic signaling pathways. Protein phosphatase magnesium-dependent 1A (PPM1A) has
recently emerged as an important tumor suppressor as it can block a range of tumor-centric signaling pathways
through protein dephosphorylation. However, the role and regulatory mechanisms of PPM1A in HCV-infected cells
have not been reported.
Methods: Total, cytoplasmic, and nuclear PPM1A protein after HCV infection or overexpression of HCV nonstructural
protein 3 (NS3) were detected by western blotting. The expression of PPM1A in normal liver and HCV-related HCC
tissues was quantified by immunohistochemistry. The effects of HCV infection and NS3 expression on the PPM1A
protein level were systematically analyzed, and the ubiquitination level of PPM1A was determined by precipitation
with anti-PPM1A and immunoblotting with either anti-ubiquitin or anti-PPM1A antibody. Finally, the roles of
NS3 and PPM1A in hepatoma cell migration and invasion were assessed by wound healing and transwell
assays, respectively.
Results: HCV infection and replication decreased PPM1A abundance, mediated by NS3, in hepatoma cells.
Compared to normal liver tissues, the expression of PPM1A was significantly decreased in the HCC tumor
tissues and adjacent non-tumor tissues. NS3 directly interacted with PPM1A to promote PPM1A ubiquitination
and degradation, which was dependent on its protease domain. Blockade of PPM1A through small interfering
RNA significantly promoted HCC cell migration, invasion, and epithelial mesenchymal transition (EMT), which
were further intensified by TGF-β1 stimulation, in vitro. Furthermore, restoration of PPM1A abrogated the NS3-
mediated promotion of HCC migration and invasion to a great extent, which was dependent on its protein
phosphatase function.
Conclusions: Our findings demonstrate that the HCV protein NS3 can downregulate PPM1A by promoting its
ubiquitination and proteasomal degradation, which might contribute to the migration and invasion of hepatoma cells
and may represent a new strategy of HCV in carcinogenesis.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide, particularly in China [1]. It
ranks as the fifth most common malignancy and the sec-
ond leading cause of cancer deaths worldwide, with
more than 695,900 deaths each year. Chronic hepatitis C
virus (HCV) infection is one of the most important risk
factors for developing HCC [2]. Approximately 200 mil-
lion people are infected with HCV worldwide, and up to
80% of infected individuals progress to chronic hepatitis,
which results in liver cirrhosis and HCC in many cases
[3, 4]. Although some progress has been made, the
mechanism underlying HCV-associated hepatocarcino-
genesis remains not fully understood.
HCV is a positive single-stranded RNA virus with an
exclusively cytoplasmic life cycle. Unlike hepatitis B virus
(HBV), which is a DNA virus that can induce insertional
mutagenesis, HCV does not insert into the host cell gen-
ome [5]. Although the inflammation caused by chronic
hepatitis C is likely to contribute to the development of
HCC, there is strong evidence that one or more of the
viral proteins and its involvement in interrupting cellular
signaling pathways contribute mostly to tumorigenesis
[6]. Multiple cellular signaling pathways including the
Wnt/β-catenin, p53, pRb, MAPK pathways, and particu-
larly, the TGF-β/smad pathway, have been implicated in
hepatocarcinogenesis [6–8]. TGF-β appears to play an
important role in the pathogenesis of HCC and is con-
sidered a hallmark of HCC because it is elevated in the
serum, tissue, and urine of patients and the increased
levels correlate with tumor progression and survival [9–11].
Furthermore, TGF-β can induce a protumoral tran-
scriptional program in cells that express HCV subge-
nomic replicon [12]. Moreover, previous studies have
shown that blockade of the TGF-β signaling pathway
using inhibitors dramatically suppresses HCC cell inva-
siveness and metastasis [13]. As these signaling path-
ways are all associated with the development of HCC,
targeting and/or blocking of these pathways can be ex-
pected to contribute to new strategies for suppressing
tumorigenesis and disease progression.
PPM1A, also known as PP2Cα, is a protein phosphat-
ase that belongs to the Protein Phosphatase 2C family.
PPM1A has recently emerged as an important tumor
suppressor owing to its involvement in the regulation of
several tumor-centric signaling pathways, including
TGF-β/smad [14], Wnt/β-catenin [15], MAPK [16],
PI3K/Akt [17], and NF-κB [18, 19]. The regulation of
these pathways has been attributed to PPM1A phosphat-
ase activity towards important pathway components
(e.g., p-Smad2/3 in TGF-β, Axin in Wnt, p38 in MAPK,
p85 subunit of PI3K in PI3K, and RelA and IKKβ in NF-
κB). Moreover, overexpression of PPM1A led to cell
cycle arrest in G2/M and apoptosis by inducing both the
expression and transcriptional activity of p53, although
it remains unclear how PPM1A modulates p53 activity
[20]. Importantly, several tumor tissues, including meta-
static human prostate and bladder carcinomas, have shown
decreased or loss of PPM1A expression [18, 21]. This indi-
cates that modulation of the protein level of PPM1A might
be an effective strategy for the abnormal activation of
the signal pathway in tumor progression. However, the
expressional regulation and distinct functions of PPM1A
in regulating tumor cells remain largely unknown.
In this study, we examined the expression of PPM1A
in HCV-infected hepatoma cells and HCV-related HCC
tissues, and we determined whether this protein is in-
volved in HCV-related HCC development. We found a
direct link between HCV infection and cellular abun-
dance of PPM1A in both hepatoma cells and the HCC
tissues. The mechanism by which NS3 downregulates
PPM1A abundance was revealed, and the roles of
PPM1A in regulating hepatoma cell invasion and migra-
tion were assessed in vitro. Together, our findings pro-
vide novel evidence on the mechanisms involved in
HCV-mediated progression of HCC, which may provide
potential candidates for the clinical prevention and treat-
ment of HCV-associated HCC.
Methods
Cell culture and virus preparation
Human HCC cells (Huh-7 and Huh-7.5.1) and embryo kid-
ney cells (HEK293T) were purchased from the China Cen-
ter for Typical Culture Collection (Wuhan, China). Cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin and streptomycin in an incubator at
37 °C with 5% CO2. The genotype 2a HCV strain JFH1 was
kindly gifted by Dr. Ying Zhu. Three days after infection of
Huh-7.5.1 cells with JFH1, cell culture supernatant con-
taining HCV particles (HCVcc) was collected, filtered using
a 0.45-μm filter, and stored at −80 °C for later infection of
Huh-7 cells. HCV titers were measured using a HCV RNA
qPCR Diagnostic Kit (KHB Co., Shanghai, China).
Reagents and antibodies
Protein synthesis inhibitor cycloheximide (CHX, 300 μM),
proteasome inhibitor MG132 (20 μM), and autophagy
inhibitor chloroquine (diphosphate salt, 50 μM) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). All in-
hibitors were dissolved in DMSO and used at the final
concentrations indicated above. Recombinant Human
TGF-β1 was purchased from PeproTech (Rocky Hill, NJ,
USA), dissolved in citric acid buffer (10 mM, pH 3.0) at a
concentration of 1 mg/ml, and used at a final concentra-
tion of 200 pM.
Mouse monoclonal antibodies against HCV NS3 and
core protein were obtained from Abcam (Cambridge, MA,
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USA) and Thermo Fisher Scientific (Waltham, MA, USA),
respectively. Rabbit polyclonal antibody against HCV NS5A
was purchased from ViroGen (Watertown, MA, USA).
Antibodies against PPM1A, E-cadherin, N-cadherin, and
vimentin were purchased from Cell Signaling Technology
(Danvers, MA, USA), and antibodies against Flag and GFP
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Clinical specimens and immunohistochemistry
Twelve pairs of HCV-related HCC tumor tissues and
matched adjacent non-tumor tissues, and 10 normal
liver tissue samples were collected at the Department of
Pathology, Union Hospital, Tongji Medical College of
Huazhong University of Science and Technology, between
2015 and 2016. The study was approved by the ethics
committee of Tongji Medical College, and informed
consent was obtained from all participants. Immuno-
histochemical staining analyses were performed using
4-μm formalin-fixed paraffin-embedded tissue sections.
The sections were deparaffinized, rehydrated, and incu-
bated in EDTA at 120 °C for 5 min for antigen retrieval.
After incubation with 3% H2O2 at room temperature
for 15 min, the sections were blocked with fetal bovine
serum and incubated with primary antibodies overnight.
Immunodetection was performed with HRP-conjugated
goat anti-rabbit antibody. Finally, the immune complexes
were visualized with a chromogenic substrate (DAB;
DAKO, Glostrup, Denmark), and the sections were coun-
terstained with hematoxylin.
The score of PPM1A staining was determined and
evaluated as described by Soslow RA et al. [22]. Briefly,
the staining intensity was evaluated independently by
two experienced pathologists and was given a score from
0 to 3 (0 = no, 1 = weak, 2 = moderate, 3 = strong stain-
ing). The intensity score was multiplied by the propor-
tion of cells stained (%) to give a final score.
Plasmids and transfection
Flag-PPM1A (pRK5F) and Flag-PPM1A D239N (pRK5F),
the phosphatase-dead mutant of PPM1A, were provided
as a gift by Dr. Xinhua Feng [14]. Flag-tagged expression
plasmids for HCV core, P7, E1, E2, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B proteins (pCMV-tag2B) were
generously gifted by Dr. Ying Zhu. To construct the
GFP-tagged NS3 and NS3 deletion constructs (protease
and helicase domains of NS3), corresponding sequences
were amplified by PCR using Flag-NS3 as the template and
were subcloned into the pGFP vector (Clontech Laborator-
ies Inc., Mountain View, CA, USA) to derive pGFP-NS3,
pGFP-protease, and pGFP-helicase. Site-directed mutagen-
esis was carried out according to the manufacturer’s in-
structions (TransGen Biotech, Beijing, China) to convert
the serine codon at position 139 of wild-type NS3 to an
alanine codon to create a protease-inactive mutant of NS3,
called S139A. All constructs containing PCR fragments
were confirmed by DNA sequencing.
Cells were grown to 50% confluence in 6-well plates,
and transfections were conducted with Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s instructions. In all co-transfection experi-
ments, corresponding vectors were used as negative con-
trols to ensure similar DNA concentrations. Cells were
either used at 24 h post-transfection for wound healing
and invasion assay, or at 36 h for western blotting.
RNA interference analysis
Short interfering RNA (siRNA) against PPM1A (si-
PPM1A) and negative control (si-NC) with nonspecific
targeting sequences were synthesized by GenePharma
Co. (Shanghai, China). The sequences were as follows:
PPM1A siRNA 1 (5′-GTACCTGGAATGCAGAGTA-
3′); PPM1A siRNA 2 (5′-GTCGACACCTGTTTGTA
TA-3′); NC (non-targeting) siRNA (5′-TTCTCCGAA
CGTGTCACGT-3′). Huh-7 cells were grown to 40%
confluence in 6-well plates and transiently transfected
with 100 nM siRNAs using Lipofectamine 2000. The
cells were used either for in vitro wound healing and in-
vasion assays after 24 h of transfection or for western
blotting after 36 h.
RNA isolation and quantitative reverse transcription
(qRT-)PCR
Total RNA was extracted from cells using Trizol reagent
(Invitrogen) and mRNA was reverse transcribed using a
Revert Aid First-Strand cDNA Synthesis Kit (Thermo
Fisher) according to the manufacturer’s instructions. qPCR
was carried out with 2× SYBR Green Mix (Thermo Fisher)
on a LightCycler 480II (Roche). The primers used in
real-time PCR were as follows:
GAPDH: (F: 5′-GGTGAAGGTCGGAGTCAACGG-3′;
R: 5′-GAGGTCAATGAAGGGGTCATTG-3′), PPM1A:
(F: 5′-CGCTGGAGAAAGAACGAAT-3′; R: 5′-TCTCTA
TCTGCCCACAGCCTAC-3′). HCV: (F: 5′-TCTGCGGA
ACCGGTGAGTA-3′; R: 5′-TCAGGCAGTACCACA
AGGC-3′). The data were normalized to that of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Relative expression was calculated using the 2-ΔΔCt method.
Western blotting
Total protein was extracted using RIPA protein lysis
buffer (Beyotime, Shanghai, China) with freshly added
1% protease inhibitor cocktail and 1 mM phenylmethyl-
sulfonyl fluoride (PMSF). Cell fractions were prepared
using a Nuclear and Cytoplasmic Protein Extraction Kit
(Beyotime) according to the manufacturer’s protocol. In
total, 50 μg of protein was used for western blotting.
Samples were separated by SDS-PAGE and transferred
onto PVDF membranes. After blocking in 5% skim milk,
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the PVDF blots were incubated with primary antibodies
in blocking buffer overnight at 4 °C and then with HRP-
conjugated secondary antibody for 2 h. Reactive bands
were visualized with ECL reagent (Pierce, Rockford, IL)
and analyzed. Protein expression was quantified using
ImageJ software.
Co-immunoprecipitation
Cells were washed twice with ice-cold PBS and lysed in
Triton-lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 5 mM EDTA, 2 mM dithiothreitol (DTT), 0.5%
Triton X-100, 1% protease inhibitor cocktail, and 1 mM
PMSF]. The lysates were centrifuged at 12,000 × g for
10 min at 4 °C and supernatant was precleared with
20 μL Protein A/G PLUS-Agarose (Santa Cruz, CA,
USA) for 1 h at 4 °C. The lysates were incubated with
the appropriate antibody overnight at 4 °C, followed by
precipitation with protein A/G PLUS-Agarose. The im-
munoprecipitates were collected by washing and centri-
fugation for three times, boiled in 2× SDS sample buffer,
and subjected to western blotting.
Immunofluorescence staining
Cells grown on coverslips were washed twice with ice-
cold PBS, fixed in 4% paraformaldehyde, permeabilized
with 0.3% Triton X-100 for 10 min, and blocked with 3%
bovine serum albumin. Then, the cells were incubated
with primary antibodies, followed by Alexa Fluor 488- or
Alexa Fluor 594-conjugated secondary antibody (Molecu-
lar Probes, OR, USA). Nuclei were stained with DAPI.
In vitro invasion assay
Twenty-four-well transwell plates with 8-μm pore-size
polycarbonate membrane inserts (Corning, NY, USA)
were precoated with 80 μL of 1:8 DMEM-diluted Matrigel
(BD Biosciences, CA, USA). Cells (5 × 104) were seeded in
serum-free medium in the top chamber and allowed to
invade into the lower chamber, which contained 20% FBS
as a chemoattractant. TGF-β1 or vehicle was added to the
upper and lower chambers. After 24 h, cells that had in-
vaded into the lower surface of the membrane were fixed
in 100% methanol, stained with 0.1% crystal violet, and
quantified by counting in five random fields.
In vitro wound healing assay
Cells grown to confluence in 24-well transwell plates
were manually scratched with a micropipette tip to create
uniformly sized wounds. Then, the cell culture medium
was replaced with fresh FBS-free medium, and TGF-β1 or
vehicle was added as required. Four points were randomly
selected and marked for each scratch, and healing wounds
were imaged at 36 h. The percentage of wound closure
was calculated based on the initial measurement for
that point at time point zero.
Statistical analysis
All values are presented as the mean ± standard error
(SEM) from at least three independent experiments. Dif-
ferences between group means were determined using a
two-tailed Student’s t-test or one-way ANOVA. A P-value
<0.05 was considered statistically significant.
Results
HCV infection downregulates PPM1A abundance
To investigate the effect of HCV infection on PPM1A
abundance, a genotype 2a virus strain, JFH1, was used to
infect the human hepatic cell line Huh-7, which is highly
permissive for HCV replication. HCV infection levels
were quantified at both protein and RNA levels with the
employment of immunoblotting and RT-qPCR analyses,
respectively (Fig. 1b and Additional file 1: Figure S1).
The results showed that PPM1A abundance was signifi-
cantly reduced within 2–3 days of infection with JFH1
(Fig. 1c), and the PPM1A level at 5 days after infection
was approximately 30% that of uninfected cells as indi-
cated by the immunoblots. Cells were further separated
into nuclear and cytoplasmic fractions. As shown in
Fig. 1d and e, nuclear expression of PPM1A decreased
more dramatically than total PPM1A, while the cytoplas-
mic abundance slightly increased during this period. Im-
munofluorescence analysis confirmed the strikingly lower
abundance of PPM1A in HCV-infected cells. In mock-
infected cells, PPM1A was mainly localized in the nucleus.
In contrast, in HCV-infected cells, PPM1A showed a
striking relocalization to the cytoplasm, in which HCV
replicated and completed its life cycle (Fig. 1f).
To further examine how HCV affects the expression of
PPM1A in HCC, we used immunohistochemistry to as-
sess the expression levels of PPM1A in HCV-related
HCC and normal liver tissues. As shown in Fig. 1g, com-
pared with the normal liver tissues, significantly lower
levels of PPM1A were found in the HCC tumor and
adjacent tissues. In addition, there were no significant
differences in PPM1A expression between tumor tissues
and the paired adjacent non-tumor tissues. Together,
these results provided strong evidence that PPM1A is
downregulated in HCV-infected hepatoma cells.
NS3 protein mediates the regulation of PPM1A
We hypothesized that the reduction in PPM1A abundance
might be mediated by one or more viral proteins expressed
during infection. Thus, we constructed a panel of expres-
sion plasmids involving all 10 HCV proteins with N-
terminal epitope tags and transfected these into Huh-7
cells to screen for their ability to downregulate PPM1A
expression. Transient transfection of NS3, but not other
HCV proteins, significantly reduced PPM1A expression
(Fig. 2a). A previous study on the virus-host protein–pro-
tein interaction network during HCV infection recently
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Fig. 1 PPM1A abundance is negatively regulated in HCV-infected cells. a Schematic representation of the experiments shown in (b–e). Huh-7 cells
were infected with JFH1 virus for 0–5 days at 1 multiplicity of infection (MOI) at intervals, and subsequently lysed simultaneously for immunoblot
analysis. Hollow bars show uninfected cells; shaded bars, infected cells. b Levels of HCV infection in Huh-7 cells were determined by immunoblotting
for HCV NS5A and core protein as described in a. c–e Total (c), nuclear (d), and cytoplasmic (e) PPM1A protein levels were measured by western
blotting. The bar graph (mean ± SEM) displays protein quantification (n = 3). Data are normalized to a loading control (tubulin for total
and cytoplasmic PPM1A, and lamin A/C for nuclear PPM1A) and expressed as the fold change relative to the protein levels in uninfected
cells. f Cells were infected or not with JFH1 for 3 days, and the subcellular localization of PPM1A was monitored by dual immunolabeling
of HCV core protein (green) and PPM1A (red). Arrows denote HCV-infected cells in which PPM1A expression and subcellular localization
are significantly changed. g Immunohistochemistry was used to measure the expression of PPM1A (brown staining) in normal liver tissues
(n = 10), and HCV-related HCC tissues and adjacent tissues (n = 12 each). g Immunohistochemistry was used to measure the expression of
PPM1A (brown staining) in normal liver tissues (n = 10), and HCV-related HCC tissues and adjacent tissues (n = 12 each). Arrows indicate
representative staining of PPM1A. Left panels show representative images of PPM1A expression, quantitative data are shown in the right panel. Data
are the mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 as evaluated using Student’s t-test or one-way ANOVA
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reported that NS3 protein could interact with PPM1A [22].
To confirm the effect of NS3 on PPM1A abundance in this
model, Huh-7 cells were transfected with increasing doses
of NS3. As shown in Fig. 2b, NS3 downregulated PPM1A
in a dose-dependent manner.
NS3 is a serine protease that cleaves its substrates
[23]. It is possible that the reduction of PPM1A is caused
by its protease activity. Thus, a protease-inactive mutant
of NS3, S139A, was constructed [24]. S139A had the same
effect as the wild type on the expression of PPM1A
(Fig. 2c), indicating that the protease activity is not neces-
sary for the effect of NS3 on PPM1A expression.
Full-length NS3 and the NS3 protease domain are dif-
fusely distributed in the cytoplasm and nucleus in the
absence of the cofactor NS4A, while in the presence of
NS4A, NS3 is localized exclusively in the cytoplasm
[25]. The current study confirmed the cytoplasmic and
nuclear distribution of NS3. Furthermore, it was shown
that in GFP- and non-transfected cells, PPM1A was
localized mainly in the nucleus. In contrast, in NS3-
transfected cells, PPM1A demonstrated a more diffuse
pattern throughout the cytoplasm and the nucleus, and
total fluorescence intensity was strikingly reduced (Fig. 2d).
Collectively, these results suggested that the HCV protein
NS3 is sufficient to modulate the abundance and cellular
localization of PPM1A.
NS3 interacts with PPM1A
It was hypothesized that NS3 might downregulate
PPM1A through its interaction with PPM1A. Hence, we
Fig. 2 NS3 is responsible for the regulation of PPM1A abundance. a–c Huh-7 cells were transiently transfected with plasmid encoding one of the
indicated HCV proteins (a), Flag-vector or Flag-NS3 plasmids at different concentrations as indicated (b), and NS3 or NS3 S139A plasmids (c) for
48 h and subsequently collected for western blotting. d Huh-7 cells were transfected with GFP-vector, GFP-NS3 or GFP-protease for 48 h and subsequently
stained for PPM1A (red); the intracellular localization of PPM1A was examined by fluorescence microscopy
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first examined whether NS3 interacts with endogenous
PPM1A in Huh-7 cells. Huh-7 cells were transfected
with Flag-NS3 plasmid and co-immunoprecipitation ex-
periments were performed, which indicated that NS3 in-
teracts with endogenous PPM1A in Huh-7 cells (Fig. 3a).
In addition, we co-transfected HEK 293 T cells with GFP-
NS3 and Flag-PPM1A; the results showed that NS3 also
interacts with exogenously expressed PPM1A (Fig. 3b).
To determine which domain(s) of NS3 mediates its
interaction with PPM1A, two deletion constructs were
made to separately express either the protease (aa 1–
180) or the helicase (aa 181–631) domain of NS3. Co-
immunoprecipitation revealed that while the protease
domain of NS3 interacted with PPM1A, the helicase do-
main did not (Fig. 3c). This suggested that the protease
domain is responsible for the interaction of the full-
length NS3 with PPM1A. Similarly, the protease domain
of NS3 could translocate PPM1A from the nucleus to
the cytoplasm (Fig. 2d). These results suggested that
NS3 interacts with PPM1A through its protease domain.
HCV infection and NS3 expression promote ubiquitin-
mediated proteasomal degradation of PPM1A
Next, the mechanism underlying the decrease in PPM1A
induced by HCV infection or NS3 expression was sys-
tematically explored. First, PPM1A mRNA levels were
measured by qRT-PCR in Huh-7 cells infected with
HCVcc for 5 days. PPM1A mRNA was upregulated in
HCV-infected cells from 2 days after infection (Fig. 4a, left
panel). Similarly, ectopic expression of NS3 significantly
elevated the PPM1A mRNA level (Fig. 4a, right panel),
likely owing to compensation. Subsequently, we assessed
the protein stability of PPM1A in NS3-expressing cells
after treatment with cycloheximide, a protein synthesis
inhibitor. The results showed that the stability of the
PPM1A protein was decreased in NS3-expressing cells
(Fig. 4b). Together, these results provided strong evidence
that NS3 modulates the level of PPM1A via posttranscrip-
tional regulation.
Eukaryotic cells use the ubiquitin proteasome system
(UPS) and autophagy lysosome pathway (ALP) as major
Fig. 3 NS3 protein interacts with PPM1A. a–c Huh-7 cells were transiently transfected with Flag-NS3 or vector (a); HEK293T cells were cotransfected
with Flag-PPM1A and GFP-NS3 (b). HEK293T cells were cotransfected with Flag-PPM1A and GFP-protease or GFP-helicase (c), 36 h later, co-IP was
performed to identify the interaction between PPM1A and NS3 or its deletion mutants
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protein degradation pathways [26]. Treatment of NS3-
transfected cells with UPS inhibitor MG132 or ALP inhibi-
tor chloroquine revealed that MG132 almost completely
abolished the effect of NS3 on the PPM1A protein level
(Fig. 4c). This indicated that NS3 might affect the protea-
somal degradation of PPM1A.
Fig. 4 HCV infection and NS3 expression promote the degradation of PPM1A via the ubiquitin proteasome pathway. a Huh-7 cells were infected
with JFH1 for 0–5 days as described in Fig. 1a (left panel). The cells were transfected with vector or NS3 for 36 h (right panel), and subsequently, the
PPM1A mRNA level was determined by qRT-PCR. Data (n = 3) were normalized to GAPDH and presented as the fold change as compared with control
cells. b–c Huh-7 cells were transfected with vector or NS3 for 36 h and subsequently treated with CHX (300 μM) for 0–3 h as indicated (b), vehicle
(DMSO), MG132 (20 μM) or chloroquine (50 μM) for 12 h (c). PPM1A protein levels were detected by immunoblotting. d–e Huh-7 cells were infected
with JFH1 virus (MOI ~0.5) for 72 h (d), transfected with Flag-vector or Flag-NS3 for 36 h (e), and treated with MG132 (20 μM) for 12 h. The cells were
lysed and subjected to immunoprecipitation with antibody against PPM1A and analyzed by western blotting with antibodies against the indicated
proteins. Arrows in the anti-ubquitin blots indicate the position of unmodified PPM1A proteins
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Since ubiquitination is generally enhanced prior to
proteasomal degradation [27], we examined whether HCV
infection and NS3 expression enhanced the ubiquitination
of PPM1A. Huh-7 cells were infected with JFH1 virus for
72 h, then treated without or with MG132 for 12 h, and
immunoprecipitation experiments with an antibody spe-
cific for PPM1A were performed. Ubiquitinated PPM1A
was detected using an anti-ubiquitin antibody. Apparently,
the levels of ubiquitinated PPM1A were significantly
higher in HCV-infected than in control cells (Fig. 4d).
Moreover, NS3 overexpression also elevated the ubiquiti-
nated PPM1A levels (Fig. 4e). Taken together, these results
indicated that HCV NS3 protein downregulates PPM1A
protein level by promoting its ubiquitin-dependent pro-
teasomal degradation.
PPM1A overexpression reverses NS3-mediated enhancement
on cell invasion
To prove that downregulation of PPM1A is involved in
NS3-induced promotion of HCC metastasis, we restored
the level of PPM1A in cells expressing NS3 and then
measured the cell migration and invasion capacities
using wound healing and transwell invasion assays. As
shown in Fig. 5c, PPM1A D239N, the phosphatase-dead
mutant of PPM1A, exhibited increased gel migration as
compared to its wild-type counterpart. This phenomena
was reported previously by Lin et al. [14], likely reflecting
a structural role of this residue. In any case, transfection
of 0.5 μg of PPM1A and D239N leveled PPM1A expres-
sion of NS3-transfected cells to nearly that of control cells.
Moreover, wound healing and transwell invasion assays
revealed that while NS3 alone enhanced cell migration
and invasion, co-transfection of NS3 and PPM1A partially
reversed this promotional effect, which indicates that the
suppression of PPM1A by NS3 might be a novel mechan-
ism of HCV in tumorigenesis (Fig. 5a and b).
Epithelial-mesenchymal transition (EMT) has been as-
sociated with the acquisition of motility, invasiveness, and
self-renewal traits in HCC cells [28]. In this study, sole ex-
pression of the viral protein NS3 significantly increased
vimentin and N-cadherin expression and decreased E-
cadherin expression, while restoration of PPM1A expres-
sion nearly abrogated the EMT-promoting effect of NS3
(Fig. 5c). Moreover, we found that the phosphatase-dead
mutant PPM1A D239N could not abolish the enhancing
effect of NS3, which suggests that the function of PPM1A
depends on its phosphatase activity (Fig. 5a and b). To-
gether, these results suggested that the cellular invasion
capacity caused by NS3 is mediated at least partially
through the modulation of PPM1A abundance.
Fig. 5 Restoration of PPM1A abundance partially reverses NS3-mediated enhancement of cell invasion. a–b After transfection with vector, NS3,
NS3 and PPM1A, NS3 and PPM1A D239N, respectively, the migration and invasion capacities of Huh-7 were analyzed by wound closure (a) and
transwell invasion (b) assays. c The protein levels of PPM1A, NS3, vimentin, E-cadherin and N-cadherin were measured by western blotting after
transfection with plasmids indicated above. Data are the mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 as evaluated using Student’s t-test
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Downregulation of PPM1A promotes the invasive capacity
of Huh-7 cells in vitro, and this promotional effect is
intensified by TGF-β1 stimulation
To assess the role of PPM1A in regulating HCC cell in-
vasiveness, we used RNA interference to examine the
impact of PPM1A knockdown on Huh-7 cell migration
and invasion capacities. Western blot and RT-PCR ana-
lyses revealed that the use of pools that consists of two
different specific siRNAs allowed reducing endogenous
PPM1A protein by over 70% relative to the level in control
cells (Fig. 6a and b). Taking into account the role of
PPM1A in TGF-β signaling, we further examined whether
the PPM1A-mediated inhibition of the TGF-β signaling
pathway would sensitize cells to TGF-β stimulation.
The wound healing assay demonstrated that PPM1A-
knockdown cells showed significantly faster wound
closure than control RNAi cells (Fig. 6c). In the presence
of TGF-β1, these differences were more remarkable.
Fig. 6 Knockdown of PPM1A promotes the invasive capacity of HCC cells, which is intensified by exogenous TGF-β1. a–b mRNA (a) and protein
(b) levels of PPM1A in Huh-7 cells were assessed by qRT-PCR and western blotting, respectively. Huh-7 cells were transfected with 100 nM PPM1A
siRNA (si-PPM1A) or control siRNA (si-NC) for 36 h before detection. GAPDH and tubulin served as internal controls for mRNA and protein loading,
respectively. c–d Huh-7 cells were transfected with si-PPM1A or si-NC and treated with TGF-β1 (200 pM) or vehicle. Wound healing (c) and transwell
invasion (d) assays were performed to analyze the migration and invasion ability of Huh-7 cells. e Western blot analysis for vimentin, E-cadherin, N-cadherin
protein in Huh-7 cells following transfection with si-PPM1A or si-NC. Data are the mean ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 as evaluated
using Student’s t-test
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Consistent herewith, the transwell invasion assay indicated
that PPM1A knockdown significantly enhanced invasion
by huh-7 cells, which was augmented by TGF-β1 stimula-
tion (Fig. 6d). These results indicated that the loss of
PPM1A significantly promoted HCC cell migration and
invasion in vitro, which was further intensified by TGF-
β1 stimulation.
In accordance herewith, PPM1A-knockdown cells
showed increased vimentin and N-cadherin expression,
but decreased E-cadherin expression, when compared
to control cells (Fig. 6e). These results demonstrated
that the reduced expression of PPM1A resulted in a
more pronounced EMT phenotype, which might con-
tribute to the acquisition of tumor-initiating and
malignancy-associated traits.
Discussion
Increasing experimental evidence suggests that HCV
contributes to HCC by directly modulating signaling path-
ways that promote the malignant transformation of hepa-
tocytes. Among the HCV-encoded proteins, the core
protein, NS3, NS4B, and NS5A have received much atten-
tion, since all of them possess cell-transforming potential
by interacting with a number of host factors and signaling
pathways when expressed in cell culture or transgenic ani-
mal models [6, 29]. NS3, a non-structural protein of HCV,
contains a protease and a helicase domain and plays
crucial roles in the processing of the viral polyprotein,
viral RNA replication, and translation [23]. Previous stud-
ies have shown that NS3 protein modulates various signal-
ing pathways that have transforming potential [30]. In this
study, we found a new strategy adopted by NS3 to pro-
mote the invasion and metastasis of HCC cells through
promoting the ubiquitination and degradation of PPM1A.
Although PPM1A was first identified approximately
20 years ago and a number of achievements with regard
to revealing its functions have been made, studies on the
mechanisms of PPM1A regulation have been rarely re-
ported. In this study, we found that PPM1A was strongly
downregulated and its normal nuclear localization shifted
to a mainly cytoplasmic distribution following infection of
cultured hepatoma cells with HCV. A screening of HCV
proteins revealed that NS3 was responsible for this alter-
ation. Our results are consistent with a mechanism in
which NS3 forms a complex with PPM1A, thereby accel-
erating its degradation, since we showed that the stability
of PPM1A is reduced in cells expressing NS3 protein. In
addition, we observed a restoration of PPM1A abundance
after treatment of NS3-expressing cells with proteasome
inhibitors, and the amount of ubiquitin-complex PPM1A
increased in HCV-infected as well as NS3-expressing cells,
which suggests that NS3 modulates the abundance of
PPM1A via the cellular normal protein degradation path-
way. Significantly lower levels of PPM1A were also found
in HCV-related HCC and adjacent tissues than in normal
tissues. However, our data did not reveal a direct correl-
ation between PPM1A and NS3 expression in HCC tis-
sues because of the low level of HCV antigen expression
in HCC tissues and the lack of an antibody capable of
labeling the HCV protein in infected liver tissues [31].
The participation of HCV proteins in the ubiquitina-
tion and degradation of host proteins has been reported.
Munakata et al. found that HCV NS5B protein traps ret-
inoblastoma tumor-suppressor protein (pRb) in the cyto-
plasm and subsequently recruits E6AP to this complex,
which leads to the ubiquitination and degradation of
pRb [32]. NS3 can also interact with several components
of the UPS, including the E3 ubiquitin ligase compo-
nents DDB1 [33], LUBAC [34], and SMURF2 [12], which
suggests that the utilization of the UPS by HCV proteins
has become one of the strategies of HCV for promoting
HCC progression and viral replication. However, the
precise molecular mechanism underlying the enhance-
ment of PPM1A ubiquitination by NS3 remains elusive
and warrants further studies.
Recently, PPM1A has attracted increasing interest owing
to its tumor suppressor-like activity. Lu et al. [18] found
that decreased PPM1A expression enhances prostate can-
cer metastasis and this, at least partially, depends on its
ability to inhibit NF-κB signaling. In metastatic bladder
cancer, loss of PPM1A expression significantly promoted
urinary bladder cancer cell motility, EMT in vitro, and me-
tastasis in vivo, which were dependent on the TGF-β/smad
signaling pathway [21]. Similarly, we found that knock-
down of PPM1A significantly promoted HCC cell migra-
tion and invasion in vitro, and the promotional activity
was further intensified by TGF-β1 stimulation. These re-
sults show that loss of PPM1A may play an important role
in the tumorigenesis of HCC, and that it partially depends
on the TGF-β/smad signaling pathway. Since multiple
tumor-related pathways can be modulated by PPM1A, fur-
ther studies on the exact signaling pathway and its corre-
sponding function in HCC tumorigenesis are needed.
Lin et al. [14] found that endogenous PPM1A is primar-
ily localized in the nucleus, where it dephosphorylates and
promotes the nuclear export of TGF-β-activated Smad2/3.
This study corroborated that PPM1A is normally localized
in the nucleus. When NS3 was expressed, PPM1A was
shuttled to the cytoplasm and it demonstrated a more
diffuse pattern throughout the cells. The alteration of
PPM1A subcellular localization may be partially caused by
an interaction with NS3, which localizes in the cytoplasm
in the presence of NS4A [25]. It is likely that NS3 interacts
with and traps PPM1A in the cytoplasm where HCV com-
pletes its lifecycle, thereby accelerating its degradation.
Since the effect of PPM1A on TGF-β signaling is
dependent on its nuclear localization, we speculate that, in
addition to a decrease in the abundance of PPM1A, its
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cytoplasmic redistribution might be another means to en-
hance TGF-β signaling. It will be of great interest to explore
how the subcellular localization of PPM1A is regulated in
order to control TGF-β and other signaling pathways under
physiological and pathophysiological conditions.
Furthermore, we found that the rescue of PPM1A ex-
pression partially counteracted the promotional effect of
NS3 on HCC cell migration and invasion, and that the res-
cuing efficiency depended on its protein phosphatase func-
tion as phosphatase-dead mutants of PPM1A had no
effect. It is worth noting that restoration of PPM1A could
only partially abrogate this promotional effect, suggesting
that NS3 possesses additional carcinogenesis activity. In
fact, the oncogenic properties of NS3 may involve a
variety of signal-transduction pathways. In addition to
modulating the TGF-β pathway by targeting SMURF2 [12],
NS3 can also enhance cancer cell invasion by activating
matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2
(COX-2) through the ERK/p38/NF-κB signal cascade [35],
and interact with p53 to inhibit p53-dependent transcrip-
tion [30]. These findings strongly suggest that the inhibition
of PPM1A by NS3 may be a novel mechanism of HCV-
mediated carcinogenesis.
Interestingly, during the course of the present study,
Liu et al. [36] reported that the HBV X protein (HBX)
increased the ubiquitination and degradation of PPM1A,
which is responsible for the HBX-induced promotion of
HCC carcinogenesis. This suggests that PPM1A, a key
modulator of the signaling pathway, can be targeted and
degraded by more than one hepatitis viral protein, and
that this has become one of the strategies of the virus to
promote tumor progression.
Conclusions
We proposed a new mechanism by which HCV protein
NS3 enhances cancer cell invasion and migration through
promoting the ubiquitination and degradation of PPM1A.
These findings not only substantiate the critical role of
NS3 in developing cancer, but also suggest that strategies
to increase PPM1A expression or activity in cancer cells
could be explored as a therapeutic strategy for HCC pre-
vention and treatment. However, further studies in vivo
should be performed to validate the function and mecha-
nisms of PPM1A.
Additional file
Additional file 1: Figure S1. Huh-7 cells were infected with JFH1
(MOI = 1) for 0–5 days as described in Fig. 1a. Intracellular HCV RNA levels
were then determined by RT-qPCR. Data are normalized to GAPDH. The
error bars represent standard deviations of triplicates. (JPG 708 kb)
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